QuestionSBA
QuestionChoice
Although this would be part of a panel of investigations if the patient were to suffer adverse bleeding, it would not be a part of routine monitoring.
10028540
d
FBC
QuestionChoice
Edoxaban has no effect on platelets and thus they have no role in monitoring either the dosing or adverse effects of edoxaban.
10028539
c
Platelet count
QuestionChoice
Edoxaban as a DOAC and just like any other anticoagulant, can increase the risk of bruising. Patients being initiated on anticoagulation should be warned to look out for signs of bleeding and report these immediately.
10028537
a
Patient reports of bruising
QuestionChoice
INR is used to monitor warfarin, an alternative anticoagulant.
10028538
b
INR
QuestionChoice
Prothrombin time is not a reliable test for factor Xa inhibitors, such as Edoxaban.
10028541
e
Prothrombin time
Concept
Chapter
2693
6084
Anticoagulation
Topic
326
Medicine
18110
Case Presentation: Case Presentation: An 82-year-old man is diagnosed with non-valvular atrial fibrillation during an inpatient stay. Following discussion regarding the available options, he is commenced on edoxaban 30mg PO OD for stroke prophylaxis.



Question: Select the most appropriate monitoring option to assess for adverse effects of the drug.
a